Aging is associated with increased FGF21 levels but unaltered FGF21 responsiveness in adipose tissue by Villarroya, Joan et al.
S HO R T T A K E
Aging is associated with increased FGF21 levels but unaltered
FGF21 responsiveness in adipose tissue
Joan Villarroya1,2,* | José M. Gallego‐Escuredo2,3,* | Alejando Delgado‐Anglés2 |
Montserrat Cairó2,4 | Ricardo Moure2,4 | Mª Gracia Mateo1 | Joan C. Domingo2 |
Pere Domingo1,3,5,6,7 | Marta Giralt2,4 | Francesc Villarroya2,4
1Infectious Diseases Unit, Hospital de la
Santa Creu i Sant Pau, Barcelona, Catalonia,
Spain
2Departament de Bioquímica i Biomedicina
Molecular and Institut de Biomedicina
(IBUB), Universitat de Barcelona, Barcelona,
Spain
3Institut de Recerca Biomèdica (IRB) de
Lleida, Lleida, Spain
4CIBER Fisiopatología de la Obesidad y
Nutrición, Barcelona, Spain
5Department of Infectious Diseases,
Hospital Universitari Arnau de Vilanova,
Lleida, Spain
6Department of Infectious Diseases,
Hospital Universitari de Santa María, Lleida,
Spain
7Universitat de Lleida, Lleida, Spain
Correspondence
Francesc Villarroya, Departament de
Bioquímica i Biomedicina Molecular, Facultat
de Biologia, Universitat de Barcelona, Av.
Diagonal 643, E‐08028 Barcelona, Catalonia,
Spain.
Email: fvillarroya@ub.edu
Funding information
Instituto de Salud Carlos III, Grant/Award
Number: PI14, /00700, PI14/00063, PI17/,
00420; Ministerio de Economía y
Competitividad, Grant/Award Number:
SAF2017-85722; European Regional
Development Fund
Abstract
Fibroblast growth factor 21 (FGF21) has been proposed to be an antiaging hormone
on the basis of experimental studies in rodent models. However, circulating FGF21
levels are increased with aging in rodents and humans. Moreover, despite the meta-
bolic health‐promoting effects of FGF21, the levels of this hormone are increased
under conditions such as obesity and diabetes, an apparent incongruity that has
been attributed to altered tissue responsiveness to FGF21. Here, we investigated
serum FGF21 levels and expression of genes encoding components of the FGF21‐
response molecular machinery in adipose tissue from healthy elderly individuals
(≥70 years old) and young controls. Serum FGF21 levels were increased in elderly
individuals and were positively correlated with insulinemia and HOMA‐IR, indices of
mildly deteriorated glucose homeostasis. Levels of β‐Klotho, the coreceptor required
for cellular responsiveness to FGF21, were increased in subcutaneous adipose tissue
from elderly individuals relative to those from young controls, whereas FGF recep-
tor‐1 levels were unaltered. Moreover, total ERK1/2 protein levels were decreased
in elderly individuals in association with an increase in the ERK1/2 phosphorylation
ratio relative to young controls. Adipose explants from aged and young mice
respond similarly to FGF21 “ex vivo”. Thus, in contrast to what is observed in obe-
sity and diabetes, high levels of FGF21 in healthy aging are not associated with
repressed FGF21‐responsiveness machinery in adipose tissue. The lack of evidence
for impaired FGF21 responsiveness in adipose tissue establishes a distinction
between alterations in the FGF21 endocrine system in aging and chronic metabolic
pathologies.
Fibroblast growth factor 21 (FGF21) is a member of the endocrine
FGFs subfamily. Pharmacological treatment with FGF21 ameliorates
age‐related metabolic disorders such as insulin resistance, dyslipi-
demia, and obesity in rodents (Coskun et al., 2008; Kharitonenkov
et al., 2005), and pilot studies in humans indicate that treatment
with an FGF21‐analog has beneficial effects on hyperlipidemia and*Both authors contributed equally.
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body weight (Gaich et al., 2013). Sustained increases in FGF21 levels
attained by transgenic overexpression of FGF21 extend the lifespan
of mice (Zhang et al., 2012), suggesting that FGF21 is a pro‐longev-
ity hormone. Circulating FGF21 levels in humans increase with age
from 5 to 80 years in healthy individuals independently of body
composition (Hanks et al., 2015). In contradiction, low levels of
FGF21 are related to healthy aging in centenarians (Sanchis‐Gomar
et al., 2015). In addition, endurance exercise in elderly individuals
reduces FGF21 levels (Taniguchi, Tanisawa, Sun, Kubo, & Higuchi,
2016). Thus, it has been suggested that the increases in FGF21 that
parallel aging are related to the appearance of an age‐related
FGF21‐resistant state, as has been proposed in metabolic diseases
(Salminen, Kaarniranta, & Kauppinen, 2017). In obese and diabetic
patients, FGF21 levels are abnormally elevated and an FGF21‐resis-
tant state has been claimed to accompany these pathologies (Fisher
et al., 2010). FGF21 is produced primarily in the liver and targets
several tissues, mainly adipose tissue but also the brain and heart.
The effects of FGF21 are mediated through interactions with FGF
receptors on cell surface and require the coreceptor β‐Klotho
(Ogawa et al., 2007). In fact, expression of β‐Klotho determines the
specific responsiveness of cells to FGF21 and FGF19, another endo-
crine FGF that originates in the intestine. β‐Klotho expression and
the ratio of phosphorylated ERK (extracellular signal‐regulated
kinase) to total ERK, a marker of the extent of intracellular signaling
driven by FGF21, are reduced in adipose tissues of obese patients
with type II diabetes (Gallego‐Escuredo et al., 2015).
In this study, we analyzed FGF21 levels and alterations in the
expression of genes encoding components of the FGF21‐responsive
molecular machinery in adipose tissue from aged individuals so as to
ascertain whether altered FGF21 responsiveness that develops with
aging jeopardizes human health and/or accelerates metabolic distur-
bances associated with aging.
To this end, we studied a cohort of 28 healthy elderly individuals
(≥70 years) with no overt signs of metabolic or other pathologies
and compared them with a cohort of 35 young healthy controls
(≤40 years). Serum FGF21 levels were significantly increased in
elderly individuals compared with young healthy controls (Figure 1a).
This is in line with previous reports describing an increase in FGF21
levels with aging (Hanks et al., 2015). The levels of FGF19, an endo-
crine FGF whose effects are also mediated by β‐Klotho, were unal-
tered with aging. Thus, the inverse relationship observed between
FGF21 and FGF19 in obesity and diabetes—upregulation of FGF21
and downregulation of FGF19—(Gallego‐Escuredo et al., 2015) did
not occur in healthy elderly individuals, despite the significant
increase in FGF21 (Figure 1a). Despite the absence of overt dia-
betes, our population of aged individuals showed an increase in gly-
cemia and insulinemia relative to young individuals (Table 1), an
observation previously reported and considered an indication of
impaired functionality of general metabolic homeostasis with age
(Barzilai, Huffman, Muzumdar, & Bartke, 2012). In fact, FGF21 levels
were positively correlated with glucose levels (r = 0.197, p = 0.048),
insulin levels (r = 0.224, p = 0.038), and insulin resistance, measured
as HOMA‐IR, (r = 0.427, p = 0.005) in the studied cohort.
We obtained subcutaneous adipose tissue biopsies from elderly
(n = 13) and young control (n = 10) individuals and analyzed several
components of the FGF21‐responsive molecular machinery. We
found that expression of the β‐Klotho gene was significantly
increased in elderly individuals compared with young healthy con-
trols (Figure 1b). Expression of the gene for FGF receptor‐1 (FGFR1),
the main FGF receptor that mediates FGF21 action in adipose tissue
(Kurosu et al., 2007), was not changed. In line with gene expression
results, β‐Klotho protein levels, measured by immunoblotting, were
higher in subcutaneous adipose tissue from elderly individuals com-
pared with those from healthy young controls (Figure 1c). Moreover,
decreased ERK1/2 protein levels in elderly individuals were accompa-
nied by an increase in the extent of ERK1/2 phosphorylation, result-
ing in a significantly higher ratio of phospho‐ERK1/2 to total ERK1/2
protein in adipose tissue from elderly individuals than in those from
young controls (Figure 1c). These results suggest that abnormally
elevated FGF21 levels in healthy aging are not associated with
repressed FGF21‐responsiveness machinery of FGF21 responsive-
ness in adipose tissue, a finding that contrasts with what is observed
in obesity and diabetes (Gallego‐Escuredo et al., 2015).
Considering that ethical and practical issues precluded the func-
tional analysis of FGF21 effects on fresh adipose tissue from aged
healthy humans, a mouse model was used. Aged mice (16‐month‐
old) showed a profile of alterations relative to young (5‐month‐old)
mice that is in general consistent with human data: Plasma FGF21
levels were increased, whereas there were no signs of impaired
expression of mediators of FGF21 signaling such as FGFR1 and β‐
Klotho (see Supporting Information Appendix S1). Treatment of adi-
pose tissue explants with FGF21 in vitro caused a significant induc-
tion in the ratio of phospho‐ERK1/2 to total ERK1/2, as well as of
expression of Egr1 and c‐Fos, early‐responsive genes to FGF21
(Fisher et al., 2010). The extent of FGF21 effects was not different
in adipose tissue from aged and young mice (Figure 1d) thus sup-
porting unaltered responsiveness of aged adipose tissue to FGF21,
as suggested by human data.
An increase in systemic and local inflammation with aging has
been reported (Cevenini et al., 2010). High tumor necrosis factor
(TNF)‐α levels and local inflammation have been shown to inhibit β‐
Klotho expression in adipose tissue (Diaz‐Delfin et al., 2012), and it
has been hypothesized that a local proinflammatory environment is
responsible for β‐Klotho downregulation in obesity. Consistent with
this, we found that plasma levels of the proinflammatory cytokines,
TNFα and monocyte chemoattractant protein‐1 (MCP‐1), were signif-
icantly higher in healthy elderly individuals than in young controls
(Table 1). Moreover, expression of TNFα and MCP‐1 genes in adi-
pose tissue was increased in healthy elderly individuals compared
with young controls (Figure 1b). Thus, locally increased expression of
TNFα in aging does not appear to lead to impaired β‐Klotho expres-
sion in adipose tissue. In this context, a correlation analysis revealed
a positive correlation of systemic levels of TNFα (r = 0.376 and
p = 0.017) with circulating levels of FGF21 in the studied cohort.
Collectively, our results suggest that healthy aging is not accom-
panied by impaired responsiveness of subcutaneous adipose tissue
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to FGF21. Even if healthy elderly individuals suffered local (adipose
tissue) and systemic inflammation, β‐Klotho expression was not
impaired by proinflammatory signals. Moreover, and contrary to
expectations, expression of β‐Klotho and markers of FGF21 action in
this FGF21‐target tissue actually increased. Our findings also confirm
that healthy human aging is associated with increased FGF21,
despite the appearance of mild signs of distorted glucose homeosta-
sis and increased inflammation associated with healthy aging; in fact,
it is likely that these metabolic stressors are involved in the increase
in FGF21. Thus, either FGF21 resistance per se does not occur dur-
ing aging or tissues other than subcutaneous fat are the actual
source of such resistance. Identification of the brain as a target of
FGF21 (Kuroda et al., 2017) highlights the potential resistance to
FGF21 in the brain as a particularly relevant concept in further aging
research. In either case, these results contrast with the situation that
prevails in obesity, diabetes, and lipodystrophy (Gallego‐Escuredo
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F IGURE 1 (a) Serum levels of FGF21 (left) and FGF19 (right) in young healthy controls (≤40) and elderly individuals (≥70). Serum levels of
FGF21 and FGF19 are log‐transformed. (b) TNFα, MCP‐1, β‐Klotho, and FGFR1 mRNA expression in subcutaneous adipose tissue from young
healthy controls and elderly individuals. Values are expressed relative to 18S rRNA (means ± SEM). (c) Levels of β‐Klotho protein (left) and
ERK1/2 phosphorylation (right) in subcutaneous adipose tissue from young healthy controls and elderly individuals. Signal intensity was
determined by densitometric quantitation of protein bands in immunoblot images (six individual samples per group). Phospho‐ERK1/2 levels
were expressed relative to total ERK1/2. Membranes were stained with Coomassie Blue to normalize the amount of protein loaded. (d) Levels
of ERK1/2 phosphorylation, Egr1 mRNA, and c‐Fos mRNA in mouse adipose tissue explants from young (5‐month‐old) and aged (16‐month‐
old) mice treated with 30 nM FGF21 (four mice, triplicate explant analysis per mouse) and nontreated controls (c). All data are presented as
means ± SEMs. *p < 0.05 and **p < 0.01 for comparisons between young healthy controls and elderly individuals, and FGF21‐treated vs.
nontreated adipose explants
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et al., 2012, 2015 ). As a result, further intervention‐based studies
would be required to fully determine systemic and tissue‐specific
sensitivity to FGF21 in human aging.
There are some obvious limitations to our study. The numbers of
individuals in our cohorts were not high. For example, a separate
analysis of young and elderly individuals by biological sex did not
reveal sex‐dependent effects on any of the parameters tested (Sup-
porting Information Appendix S1), but studies on a larger number of
individuals could reinforce this negative observation. Moreover, vis-
ceral adipose tissue, a type of fat targeted by FGF21 that is espe-
cially sensitive to metabolic disease‐associated alterations, and liver,
could not be studied for the obvious reasons that such biopsies can-
not ethically be obtained from aged healthy volunteers. Further
research will be needed to determine whether other tissues follow
the same pattern of FGF21 responsiveness as subcutaneous adipose
tissue. At last, functional assessment of unaltered effects of FGF21
in adipose tissue in aged individuals relied on a mouse model. In any
case, ours is the first report that age‐related increases in FGF21 are
not associated with an impairment in the FGF21‐responsive machin-
ery in adipose tissue and establish a distinction between alterations
in the FGF21 endocrine system in aging and those in obesity and
diabetes.
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